FMP

FMP

Enter

OCGN - Ocugen, Inc.

Profile of Ocugen, Inc.(OCGN), Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies t

About

ceo

Dr. Shankar Musunuri M.B.A., Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.ocugen.com

exchange

NASDAQ

Description

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

CIK

0001372299

ISIN

US67577C1053

CUSIP

67577C105

Address

263 Great Valley Parkway

Phone

484 328 4701

Country

US

Employee

84

IPO Date

Dec 3, 2014

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep